Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR),
which has been approved in combination with exemestane for hormone receptor-positive …

Background Everolimus, an orally administered rapamycin analogue, inhibits the
mammalian target of rapamycin (mTOR), a highly conserved intracellular serine–threonine …

Breast cancer (BC) is diagnosed in nearly 1 in 3 women with cancer in the United States;
one third of these patients have regional lymph node metastases at the time of diagnosis …

Aberrations in the phosphoinositide 3-kinase/protein kinase B/mammalian target of
rapamycin pathway are common abnormalities in breast cancer and are associated with the …

The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has
brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have …

Background In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of
rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when …

Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment
of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant …

Background: Breast cancer cells can develop resistance to standard hormonal treatment
and chemotherapy with the activation of the mTOR pathway; this is supported by results of …

Simple Summary Everolimus is an oral drug used in patients with advanced hormone
receptor positive, HER2 negative breast cancer. In this study based on a national French …

The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol
3‐kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth …